Lilly's Eczema Drug Proves Effective in Long-Term Study

• Majority of patients achieved near-complete skin clearance and itch relief with up to four years of continuous treatment with the once-monthly injection
• The drug is approved for adults and children 12 years and older with moderate-to-severe eczema who cannot use topical therapies
• Safety profile remained consistent with no new issues observed, and Lilly has submitted data to the FDA for a label update based on trials showing efficacy with dosing every four or eight weeks

Eli Lilly's Eczema Drug Shows Sustained Efficacy in Four-Year Study

Eli Lilly announced Friday that its eczema treatment Ebglyss demonstrated durable efficacy in a late-stage post-marketing study, providing relief from persistent itching for up to four years in patients with moderate-to-severe atopic dermatitis.

Key Study Details:

Ebglyss, a once-monthly injectable drug approved in the U.S. in 2024, showed sustained results in patients with moderate-to-severe eczema. The treatment is indicated for adults and children aged 12 and older who cannot use topical therapies. Study results revealed that the majority of patients achieved near-complete skin clearance and itch relief with up to four years of continuous treatment.

Safety Profile:

The drug's safety profile during the first year remained consistent with its known characteristics across all dosing frequencies, with no new safety concerns identified. The study will continue for an additional year of treatment.

Regulatory Developments:

Lilly previously reported positive results from another trial demonstrating Ebglyss' durable response when administered every four or eight weeks. The company has submitted this data to the FDA for a potential label update, which could expand dosing flexibility.

Market Implications:

These long-term efficacy results strengthen Ebglyss' competitive position in the dermatology market, particularly for chronic eczema treatment where sustained symptom control is critical. The potential for extended dosing intervals (every four to eight weeks versus monthly) could improve patient convenience and treatment adherence, enhancing the drug's commercial appeal. The positive four-year data provides physicians and patients with confidence in the treatment's long-term safety and effectiveness profile.